
Basal cell carcinoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051105

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the Pharmaceutical Benefits Scheme
(PBS) subsidised sonidegib and vismodegib for patients with basal cell
carcinoma (BCC).

Basal cell carcinoma (BCC) and listing dates

Basal cell carcinoma (BCC) is a type of skin cancer arising from the
basal cells.

Listing dates are as follows:

-   vismodegib – 1 April 2017
-   sonidegib – 1 April 2018

See Written Authority Required Drugs for further information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to restriction and item codes, contact
details, application forms, and the Pharmaceutical Benefits Scheme (PBS)
and Services Australia websites.

Related links

Written Authority Required Drugs

Processing Written Authority Required Listings

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

                                   

-   Services Australia ABN 90 794 605 008 
